Generation of T cells specific for the wild-type sequence p53264-272 peptide in cancer patients: Implications for immunoselection of epitope loss variants

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5938-5944

  Hoffmann, T K ^a   Nakano, K ^a   Elder, E M ^a   Dworacki, G ^a   Finkelstein, S D ^a   Appella, E ^a   Whiteside, T L ^a   DeLeo, A B ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; PROTEIN P53;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; VACCINATION;

EID: 0034669973     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5938     Document Type: Article

References (40)

1. Combined-modality therapy of head and neck cancer
2. Cancer statistics
3. p53 Mutations in human cancers
4. Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation
5. Structure and function of the p53 tumor suppressor gene: Clues and rational cancer therapeutic strategies
6. p53-Based immunotherapy of cancer
7. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
8. Flow-cytometric determination of peptide-class-I complex formation: Identification of p53 peptides that bind to HLA-A2
9. Targeting p53 as a general tumor antigen
10. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
11. Tumor eradication by wild type p53 specific cytotoxic T lymphocytes
12. Targeting p53 for adoptive T-cell immunotherapy
13. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides
14. p53, a potential target for tumor-directed T cells
15. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors
16. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
17. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
18. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells
19. Immunology of head and neck cancer
20. The immunopharmacology of head and neck cancer: An update
21. Immune cells in the tumor microenvironment: Mechanisms responsible for signaling and functional defects
22. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer
23. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines
24. HLA class I expression in T-B lymphoblast hybrids
25. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down regulated by tumor necrosis factor alpha
26. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
27. Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assay
28. Prediction of biologic aggressiveness in colorectal cancer by p53/K-ras-2 topographic genotyping
29. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations
30. + T cells specific for EBV in healthy virus carriers
31. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope
32. The HLA-A0207 peptide binding repertoire is limited to a subset of the A0201 repertoire
33. Tolerance, danger, and the extended family
34. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
35. The use of HLA-A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire
36. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
37. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA-A0201 peptide consensus motif
38. Immunosuppression in human tumor-host interaction: Role of cytokines and alterations in signal-transducing molecules
39. Signaling defects in T lymphocytes of patients with malignancy
40. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer